Skip to main content
Betta Pharmaceuticals Co.,Ltd logo

Betta Pharmaceuticals Co.,Ltd — Investor Relations & Filings

Ticker · 300558 ISIN · CNE100002DD9 LEI · 8368009YF4Y6NC7HVB09 Shenzhen Stock Exchange Manufacturing
Open in API
Filings indexed 1,657 across all filing types
Latest filing 2016-10-25 Regulatory Filings
Country CN China
Listing Shenzhen Stock Exchange 300558

About Betta Pharmaceuticals Co.,Ltd

https://www.bettapharma.com

Betta Pharmaceuticals Co.,Ltd. focuses on the research, development, and commercialization of innovative oncology medications. The organization specializes in targeted therapies, particularly for the treatment of lung cancer and other solid tumors. Its portfolio includes Icotinib, a small-molecule EGFR tyrosine kinase inhibitor, and Ensartinib, an ALK inhibitor designed for non-small cell lung cancer. The company operates a comprehensive R&D infrastructure dedicated to molecular biology, medicinal chemistry, and clinical development. By prioritizing precision medicine, the firm aims to deliver high-quality therapeutic solutions that address complex oncological challenges. Its pipeline encompasses a diverse range of candidates, including small molecules and biologics, aimed at improving patient outcomes through advanced scientific innovation.

Recent filings

Filing Released Lang Actions
首次公开发行A股并在创业板上市发行公告
Regulatory Filings
2016-10-25 Chinese
首次公开发行股票并在创业板上市招股说明书
Regulatory Filings Classification · 95% confidence The document is a detailed prospectus for an initial public offering (IPO) and listing on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive information about the stock issuance, lock-up arrangements, profit distribution plans, stock price stabilization measures, shareholder commitments, and legal and regulatory compliance statements. The document is titled as a 招股说明书 (Prospectus) and contains detailed disclosures required for an IPO filing. This type of document is not an announcement or a brief summary but a comprehensive offering document. It does not fit into categories like Annual Report, Earnings Release, or Management Reports. It is a primary IPO prospectus document, which is best classified under Regulatory Filings (RNS) as there is no specific IPO prospectus category in the provided list. The document is too long and detailed to be a Report Publication Announcement (RPA) and contains substantive content rather than just a certification or attestation, so it is not RNS for certification. Therefore, the best fit is Regulatory Filings (RNS).
2016-10-25 Chinese
首次公开发行A股并在创业板上市网上路演公告
Capital/Financing Update Classification · 95% confidence The document is an announcement regarding the initial public offering (IPO) of A shares by 贝达药业股份有限公司, including details about the share issuance, allocation, and an online roadshow event for investors. It mentions the approval by the China Securities Regulatory Commission and provides information about the timing and participation in the roadshow. The document is short (847 characters) and serves as a notice to investors about the IPO and related investor presentation activities. It does not contain financial statements or detailed financial data, nor is it a full investor presentation document. Given the content and length, this fits best as a Capital/Financing Update (CAP) because it relates to fundraising activities and share issuance announcements, but it is not a full share issue announcement (SHA) since it focuses on the IPO process and roadshow rather than the share issuance details alone. Therefore, the most appropriate classification is CAP with high confidence.
2016-10-24 Chinese
第一届董事会第十一次会议决议
Regulatory Filings
2016-10-18 Chinese
国浩律师（杭州）事务所关于公司首次公开发行股票并在创业板上市之律师工作报告
Audit Report / Information Classification · 95% confidence The document is a detailed legal work report issued by a law firm (国浩律师（杭州）事务所) regarding the initial public offering (IPO) and listing of 贝达药业股份有限公司 on the Shenzhen Stock Exchange's Growth Enterprise Market (创业板). It includes extensive legal opinions, verification of company status, approvals, authorizations, shareholder meetings, issuance plans, and compliance with relevant laws and regulations. The document is titled as a "律师工作报告" (Lawyer Work Report) and is focused on the legal aspects of the IPO process, not on financial results or earnings. It is not a simple announcement or certification but a comprehensive legal report supporting the IPO. This type of document is a specialized legal report related to securities issuance and listing, which fits the category of Audit Report / Information (AR) as it includes legal audit and verification reports related to the IPO process, but is not the full Annual Report or financial report. Therefore, the appropriate classification is AR (Audit Report / Information). FY 2013
2016-10-18 Chinese
公司章程（草案）
Governance Information Classification · 100% confidence The document is titled as the Articles of Association (章程) of Betta Pharmaceuticals Co. Ltd., revised in March 2016. It contains detailed provisions on company governance, shareholder rights, board structure, share issuance, share transfer, shareholder meetings, and other corporate governance matters. It references Chinese company law and securities law, and includes detailed chapters on shareholders, board of directors, management, and financial accounting systems. The document is a foundational governance document for the company, not a report of financial results, audit, or meeting minutes. It is not an announcement or a brief summary but a full set of corporate bylaws. Therefore, it fits the category of Governance Information (CGR).
2016-10-18 Chinese

Browse filings by year

11 years

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.